METHOTREXATE INJECTION, USP SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

METHOTREXATE (METHOTREXATE SODIUM)

थमां उपलब्ध:

STRIDES PHARMA CANADA INC

ए.टी.सी कोड:

L01BA01

INN (इंटरनेशनल नाम):

METHOTREXATE

डोज़:

25MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

METHOTREXATE (METHOTREXATE SODIUM) 25MG

प्रशासन का मार्ग:

INTRA-ARTERIAL

पैकेज में यूनिट:

2ML/40ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

ANTINEOPLASTIC AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0107545002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2013-12-03

उत्पाद विशेषताएं

                                PAGE 1 OF 47
PRODUCT MONOGRAPH
PR
METHOTREXATE INJECTION, USP
Unpreserved
25 mg/mL methotrexate (as methotrexate sodium)
Sterile Solution
Intramuscular, intravenous, intra-arterial, intrathecal, and
intracerebroventricular
ANTIMETABOLITE AND ANTIRHEUMATIC
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7
Date of Revision:
October 14, 2021
Submission Control No.: 254503
PAGE 2 OF 47
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
13
DRUG INTERACTIONS
.........................................................................................................
16
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
........................................................................................................................
29
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
29
STORAGE AND STABILITY
.................................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 33
PART II: SCIENTIFIC INFORMATION
........................................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 14-10-2021

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें